Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;15(19):1863-9.
doi: 10.2174/092986708785132915.

Therapeutic targets in prostaglandin E2 signaling for neurologic disease

P J Cimino  1 , C Dirk Keene, Richard M Breyer, Kathleen S Montine, Thomas J Montine
Affiliations
Review

Therapeutic targets in prostaglandin E2 signaling for neurologic disease

P J Cimino et al. Curr Med Chem. 2008.

Abstract

Prostaglandins (PGs) are potent autocrine and paracrine oxygenated lipid molecules that contribute appreciably to physiologic and pathophysiologic responses in almost all organs, including brain. Emerging data indicate that the PGs, and more specifically PGE2, play a central role in brain diseases including ischemic injury and several neurodegenerative diseases. Given concerns over the potential toxicity from protracted use of cyclooxygenase inhibitors in the elderly, attention is now focused on blocking PGE2 signaling that is mediated by interactions with four distinct G protein-coupled receptors, EP1-4, which are differentially expressed on neuronal and glial cells throughout the central nervous system. EP1 activation has been shown to mediate Ca2+-dependent neurotoxicity in ischemic injury. EP2 activation has been shown to mediate microglial-induced paracrine neurotoxicity as well as suppress microglia internalization of aggregated neurotoxic peptides. Animal models support the potential efficacy of targeting specific EP receptor subtypes in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and ischemic stroke. However promising these preclinical studies are, they have yet to be followed by clinical trials targeting any EP receptor in neurologic diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kudo I, Murakami M. Prostaglandins Other Lipid Mediat. 2002;68-69:3–58. - PubMed
    1. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Prostaglandins. 1997;54:601–624. - PubMed
    1. Hata AN, Breyer RM. Pharmacol. Ther. 2004;103:147–166. - PubMed
    1. Difranco E, Subbanagounder G, Kim S, Murthi K, Taneda S, Monnier V, Salomon R. Chem. Res. Toxicol. 1994;8:61–67. - PubMed
    1. Boutaud O, Ou JJ, Chaurand P, Caprioli RM, Montine TJ, Oates JA. J Neurochem. 2002;82:1003–1006. - PubMed

MeSH terms